{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:10:48Z","timestamp":1790777448231,"version":"4.1.0"},"reference-count":181,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108950","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T06:35:04Z","timestamp":1756794904000},"page":"108950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A review: recent developments of co-targeted TRK (tropomyosin receptor kinases) inhibitors for cancer therapy"],"prefix":"10.1016","volume":"165","author":[{"given":"Paria","family":"Nasehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Omidkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Ghodsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108950_bb0005","doi-asserted-by":"crossref","first-page":"116477","DOI":"10.1016\/j.ejmech.2024.116477","article-title":"Recent advances in c-met-based dual inhibitors in the treatment of cancers","volume":"272","author":"Jin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0010","first-page":"101","article-title":"Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer, nature reviews","volume":"21","author":"Stoop","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0015","first-page":"1","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108950_bb0025","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/ijms21030753","article-title":"NTRK fusions in central nervous system tumors: a rare, but worthy target","volume":"21","author":"Gambella","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108950_bb0030","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.3390\/ijms25052732","article-title":"Neurotrophins and Trk Neurotrophin receptors in the retina of adult killifish (Nothobranchius guentheri)","volume":"25","author":"Porcino","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108950_bb0035","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2174\/0929867329666220801145639","article-title":"Research progress on small molecules inhibitors targeting TRK kinases","volume":"30","author":"Liu","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108950_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106501","article-title":"Boosting BDNF in muscle rescues impaired axonal transport in a mouse model of DI-CMTC peripheral neuropathy","volume":"195","author":"Rhymes","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bioorg.2025.108950_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116729","article-title":"Environmental enrichment and the combined interventions of EE and metformin enhance hippocampal neuron survival and hippocampal-dependent memory in type 2 diabetic rats under stress through the BDNF-TrkB signaling pathways","volume":"175","author":"Ismail","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.05.013","article-title":"Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma","volume":"365","author":"Cr\u00e9ancier","year":"2015","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108950_bb0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.108950_bb0060","doi-asserted-by":"crossref","unstructured":"T. HK, ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin, J. Neurosci. 25(22) (2005) 5455\u20135463.","DOI":"10.1523\/JNEUROSCI.5123-04.2005"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108950_bb0065","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108950_bb0070","doi-asserted-by":"crossref","first-page":"115618","DOI":"10.1016\/j.ejmech.2023.115618","article-title":"Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: a mini review","volume":"258","author":"El-Nassan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0075","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.3390\/ijms25042366","article-title":"NTRK therapy among different types of cancers, review and future perspectives","volume":"25","author":"Theik","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108950_bb0080","doi-asserted-by":"crossref","unstructured":"W. Yan, N.R. Lakkaniga, F. Carlomagno, M. Santoro, N.Q. McDonald, F. Lv, N. Gunaganti, B. Frett, H.-y. Li, Insights into current tropomyosin receptor kinase (TRK) inhibitors: development and clinical application, J. Med. Chem. 62(4) (2018) 1731\u20131760.","DOI":"10.1021\/acs.jmedchem.8b01092"},{"issue":"15","key":"10.1016\/j.bioorg.2025.108950_bb0085","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.3390\/molecules29153560","article-title":"Pyrazolo [1, 5-a] pyrimidine as a prominent framework for tropomyosin receptor kinase (Trk) inhibitors\u2014synthetic strategies and SAR insights","volume":"29","author":"Mahajan","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108950_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106563","article-title":"Discovery of novel phenyl triazole analogs as TRK\/ALK dual inhibitors with prospective antitumor effects","volume":"136","author":"Cao","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108950_bb0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cancergen.2022.03.002","article-title":"TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults","volume":"264","author":"Harada","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.apsb.2023.11.010","article-title":"Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib","volume":"14","author":"Xiang","year":"2023","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.bioorg.2025.108950_bb0105","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: the next generation anticancer agents","volume":"143","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108950_bb0110","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","article-title":"Single inhibitors versus dual inhibitors: role of HDAC in cancer","volume":"8","author":"Roy","year":"2023","journal-title":"ACS Omega"},{"issue":"23","key":"10.1016\/j.bioorg.2025.108950_bb0115","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrd1609","article-title":"Multicomponent therapeutics for networked systems","volume":"4","author":"Keith","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108950_bb0125","first-page":"297","article-title":"Systems approaches to polypharmacology and drug discovery","volume":"13","author":"Boran","year":"2010","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.bioorg.2025.108950_bb0130","doi-asserted-by":"crossref","first-page":"116109","DOI":"10.1016\/j.ejmech.2023.116109","article-title":"Advancements in dual-target inhibitors of PI3K for tumor therapy: clinical progress, development strategies, prospects","volume":"265","author":"Hu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signaling"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108950_bb0140","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.bioorg.2025.108950_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115051","article-title":"An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects","volume":"27","author":"Lei","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108950_bb0150","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/ph13120474","article-title":"The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer","volume":"13","author":"Gristina","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"69","key":"10.1016\/j.bioorg.2025.108950_bb0155","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0959-8049(16)32675-2","article-title":"TPX-0005, a novel ALK\/ROS1\/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants","volume":"1","author":"Cui","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108950_bb0160","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1021\/acs.jmedchem.2c00308","article-title":"Discovery of the first highly selective and broadly effective macrocycle-based type II TRK inhibitors that overcome clinically acquired resistance","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108950_bb0165","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion\u2013positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"2 Suppl","key":"10.1016\/j.bioorg.2025.108950_bb0170","first-page":"S15","article-title":"Diagnosis and management of TRK fusion cancer","volume":"28","author":"Kummar","year":"2022","journal-title":"Am. J. Manag. Care"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0175","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0180","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.cllc.2019.11.010","article-title":"Rapid clinical and radiologic responses with Larotrectinib treatment in a patient with TRK-fusion\u2013positive metastatic lung Cancer","volume":"21","author":"Hochmair","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bioorg.2025.108950_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116396","article-title":"Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK\/ALK dual inhibitors with promising antitumor effects","volume":"47","author":"Li","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108950_bb0190","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non\u2013small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0195","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1038\/s41467-021-24367-3","article-title":"Structural basis of the activation of c-MET receptor","volume":"12","author":"Uchikawa","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108950_bb0200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/cancers9070087","article-title":"Role and therapeutic targeting of the HGF\/MET pathway in glioblastoma","volume":"9","author":"Cruickshanks","year":"2017","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108950_bb0205","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1016\/j.celrep.2019.11.063","article-title":"LC3C-mediated autophagy selectively regulates the met RTK and HGF-stimulated migration and invasion","volume":"29","author":"Bell","year":"2019","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0210","first-page":"115","article-title":"HGF\/MET Signalling and DNA damage response: strategies to conquer radiotherapy resistance in head and neck Cancer","volume":"2","author":"Vijayakumaran","year":"2021","journal-title":"Journal of Cellular Signaling"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0215","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41419-022-04799-5","article-title":"HGF\/c-met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR\/NGF axis","volume":"13","author":"Qin","year":"2022","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108950_bb0220","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41419-023-06246-5","article-title":"A novel c-met\/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation","volume":"14","author":"An","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2025.108950_bb0225","series-title":"Substance Having Tyrosine Kinase Inhibitory Activity and Preparation Method and Use Thereof, Google Patents","author":"Yang","year":"2017"},{"key":"10.1016\/j.bioorg.2025.108950_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1104-4","article-title":"A selective c-met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth","volume":"38","author":"Luo","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6461","key":"10.1016\/j.bioorg.2025.108950_bb0235","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/367380a0","article-title":"Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor ret","volume":"367","author":"Schuchardt","year":"1994","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108950_bb0240","first-page":"571","article-title":"Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains","volume":"3","author":"Takahashi","year":"1988","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0245","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108950_bb0250","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2017.08.019","article-title":"Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing","volume":"118","author":"Zhang","year":"2018","journal-title":"Lung Cancer"},{"issue":"16","key":"10.1016\/j.bioorg.2025.108950_bb0255","doi-asserted-by":"crossref","first-page":"11747","DOI":"10.1021\/acs.jmedchem.0c02167","article-title":"Targeting rearranged during transfection in cancer: a perspective on small-molecule inhibitors and their clinical development","volume":"64","author":"Saha","year":"2021","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108950_bb0260","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/13543776.2022.2132851","article-title":"An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016\u2013present)","volume":"32","author":"Acharya","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2025.108950_bb0265","series-title":"RET Kinase Inhibitors for the Treatment of RET-Altered Thyroid Cancers: Current Knowledge and Future Directions","author":"Hamidi","year":"2024"},{"key":"10.1016\/j.bioorg.2025.108950_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113064","article-title":"The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine","volume":"150","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0275","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.108950_bb0280","series-title":"The Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and na\u00efve RET-Driven cancer Models","author":"Drilon","year":"2020"},{"key":"10.1016\/j.bioorg.2025.108950_bb0285","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1200\/PO.20.00278","article-title":"Response to Cabozantinib following acquired Entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3 G623R solvent-front mutation","volume":"5","author":"Hanf","year":"2021","journal-title":"JCO Precis. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108950_bb0290","doi-asserted-by":"crossref","first-page":"E811","DOI":"10.1210\/jc.2012-2672","article-title":"Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer","volume":"98","author":"De Falco","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0295","doi-asserted-by":"crossref","first-page":"16103","DOI":"10.1038\/s41598-021-95612-4","article-title":"Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases","volume":"11","author":"Moccia","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0300","first-page":"263","article-title":"RET receptor expression and interaction with TRK receptors in neuroblastomas","volume":"44","author":"Tetri","year":"2020","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0305","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.onc.1206980","article-title":"The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation","volume":"23","author":"Peterson","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108950_bb0310","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annonc.2021.02.010","article-title":"Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.108950_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117749","article-title":"Discovery of 9H-pyrimido [4, 5-b] indole derivatives as dual RET\/TRKA inhibitors","volume":"106","author":"Acharya","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2025.108950_bb0320","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1158\/1078-0432.CCR-21-0465","article-title":"Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer","volume":"27","author":"Laetsch","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108950_bb0325","series-title":"Pathophysiology of Atopic Dermatitis: Clinical Implications","first-page":"84","author":"Kim","year":"2019"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108950_bb0330","first-page":"590","article-title":"Atopic dermatitis: diagnosis and treatment","volume":"101","author":"Frazier","year":"2020","journal-title":"Am. Fam. Physician"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108950_bb0335","first-page":"532","article-title":"Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis","volume":"43","author":"D'Ippolito","year":"2018","journal-title":"Pharm. Therapeutics"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108950_bb0340","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J. Clinical Cellular Immunol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0345","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3390\/ijms21041314","article-title":"The role of Th17-related cytokines in atopic dermatitis","volume":"21","author":"Sugaya","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108950_bb0350","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/cells13161398","article-title":"IL-22 in atopic dermatitis","volume":"13","author":"Laska","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.108950_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113316","article-title":"Dietary glutamine supplementation improves both Th1 and Th17 responses via CARD11-mTORC1 pathway in murine model of atopic dermatitis","volume":"143","author":"Fan","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0360","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2025.108950_bb0365","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK inhibitors for atopic dermatitis: an update","volume":"20","author":"He","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.bioorg.2025.108950_bb0370","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s10875-014-0110-8","article-title":"Interleukin-2-inducible T-cell kinase (ITK) deficiency-clinical and molecular aspects","volume":"34","author":"Ghosh","year":"2014","journal-title":"J. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108950_bb0375","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.625","article-title":"Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells","volume":"11","author":"Mammadli","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.108950_bb0380","first-page":"1889","article-title":"Dual inhibition of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase a (TRKA) as potential treatment for atopic dermatitis and other inflammatory and autoimmune diseases","author":"Abdel-Magid","year":"2021","journal-title":"ACS Publ."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108950_bb0385","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00109-020-01958-z","article-title":"Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis","volume":"98","author":"Lechner","year":"2020","journal-title":"J. Mol. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108950_bb0390","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1517\/13543776.2014.936381","article-title":"Inducible tyrosine kinase inhibitors: a review of the patent literature (2010\u22122013)","volume":"24","author":"Norman","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108950_bb0395","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3390\/ijms21030699","article-title":"Current concepts in inflammatory skin diseases evolved by transcriptome analysis: in-depth analysis of atopic dermatitis and psoriasis","volume":"21","author":"Kaplan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108950_bb0400","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3390\/ijms21030699","article-title":"Current concepts in inflammatory skin diseases evolved by transcriptome analysis: in-depth analysis of atopic dermatitis and psoriasis","volume":"21","author":"Schwingen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108950_bb0405","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s12276-020-0484-z","article-title":"The M-CSF receptor in osteoclasts and beyond","volume":"52","author":"Mun","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108950_bb0410","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/s41375-018-0311-x","article-title":"Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma","volume":"33","author":"Edginton-White","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108950_bb0415","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1084\/jem.193.6.727","article-title":"Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy","volume":"193","author":"Lin","year":"2001","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108950_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050946","article-title":"Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0425","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/his.12407","article-title":"High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma","volume":"65","author":"Pedersen","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.bioorg.2025.108950_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-017-0634-1","article-title":"CSF-1R inhibitor development: current clinical status","volume":"19","author":"Peyraud","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bioorg.2025.108950_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114884","article-title":"CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment","volume":"245","author":"Wen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0440","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/13543776.2021.1839414","article-title":"Small-molecule CSF1R kinase inhibitors; review of patents 2015-present","volume":"31","author":"Denny","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2025.108950_bb0445","series-title":"NOVEL QUINOLINE DERIVATIVE INHIBITOR, EUROPEAN PATENT APPLICATION WO2020038460","author":"Wu","year":"2021"},{"issue":"3_Supplement","key":"10.1016\/j.bioorg.2025.108950_bb0450","doi-asserted-by":"crossref","first-page":"PR01-PR01","DOI":"10.1158\/2326-6074.TUMIMM16-PR01","article-title":"Abstract PR01: blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase (Trk) improves antitumor efficacy of immunotherapy","volume":"5","author":"Mok","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bioorg.2025.108950_bb0455","doi-asserted-by":"crossref","unstructured":"S. Mok, C. Duffy, R. Du, J.P. Allison, Abstract A146: increase antitumor activity of immunotherapy by blocking colony stimulating factor 1 receptor and tropomyosin receptor kinase, Cancer Immunol. Res. 4 (11_Supplement) (2016) A146-A146.","DOI":"10.1158\/2326-6066.IMM2016-A146"},{"key":"10.1016\/j.bioorg.2025.108950_bb0460","series-title":"Compound, Certain Novel Forms Thereof, Pharmaceutical Compositions Thereof and Methods for Preparation and Use","author":"Su","year":"2011"},{"issue":"26","key":"10.1016\/j.bioorg.2025.108950_bb0465","doi-asserted-by":"crossref","first-page":"42076","DOI":"10.18632\/oncotarget.14942","article-title":"Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108950_bb0470","series-title":"Surufatinib in US Patients with Soft Tissue Sarcoma","author":"Movva","year":"2022"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108950_bb0475","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1111\/jcmm.13181","article-title":"Dual inhibition of BDNF\/TrkB and autophagy: a promising therapeutic approach for colorectal cancer","volume":"21","author":"Mazouffre","year":"2017","journal-title":"J. Cell. Mol. Med."},{"issue":"10147","key":"10.1016\/j.bioorg.2025.108950_bb0480","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.108950_bb0485","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2019.06.002","article-title":"Dual FLT3 inhibitors: against the drug resistance of acute myeloid leukemia in recent decade","volume":"178","author":"Yuan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0490","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00062752-200207000-00003","article-title":"Role of FLT3 in leukemia","volume":"9","author":"Gilliland","year":"2002","journal-title":"Curr. Opin. Hematol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0495","first-page":"178","article-title":"FLT3 mutations: biology and treatment","volume":"2006","author":"Small","year":"2006","journal-title":"ASH Education Program Book"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0500","first-page":"261","article-title":"Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells","volume":"10","author":"Dehmel","year":"1996","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0505","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/10428194.2013.800198","article-title":"FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations","volume":"55","author":"Kayser","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108950_bb0510","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/annonc\/mdw015","article-title":"New drugs in acute myeloid leukemia","volume":"27","author":"Kadia","year":"2016","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.bioorg.2025.108950_bb0515","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1158\/1078-0432.CCR-09-1070","article-title":"Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology","volume":"15","author":"Ellis","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108950_bb0520","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1172\/JCI120787","article-title":"Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies","volume":"128","author":"Taylor","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"24","key":"10.1016\/j.bioorg.2025.108950_bb0525","first-page":"2159","article-title":"Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms","volume":"135","author":"Joshi","year":"2020","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"53","key":"10.1016\/j.bioorg.2025.108950_bb0530","doi-asserted-by":"crossref","first-page":"30092","DOI":"10.18632\/oncotarget.25723","article-title":"Characterization of TRKA signaling in acute myeloid leukemia","volume":"9","author":"Herbrich","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108950_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116596","article-title":"Discovery of a benzimidazole-based dual FLT3\/TrKA inhibitor targeting acute myeloid leukemia","volume":"56","author":"Dokla","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121177","article-title":"Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)","volume":"10","author":"Zorn","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108950_bb0545","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13543776.2021.1890027","article-title":"Aurora kinase inhibitors: a patent review (2014-2020)","volume":"31","author":"Jing","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108950_bb0550","doi-asserted-by":"crossref","first-page":"12893","DOI":"10.18632\/oncotarget.7335","article-title":"MLN-8237: a dual inhibitor of aurora a and B in soft tissue sarcomas","volume":"7","author":"Nair","year":"2016","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.bioorg.2025.108950_bb0555","doi-asserted-by":"crossref","first-page":"23937","DOI":"10.18632\/oncotarget.14893","article-title":"Aurora kinases: novel therapy targets in cancers","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0560","first-page":"179","article-title":"Human TPX2 is required for targeting Aurora-a kinase to the spindle","volume":"54","author":"Kufer","year":"2003","journal-title":"Cell Motil. Cytoskeleton"},{"key":"10.1016\/j.bioorg.2025.108950_bb0565","first-page":"295","article-title":"Aurora-a kinase as a promising therapeutic target in cancer","volume":"5","author":"D'Assoro","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108950_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrfmmm.2020.111716","article-title":"Aurora kinases and DNA damage response","volume":"821","author":"Ma","year":"2020","journal-title":"Mutation Research\/Fundamental and Molecular Mechanisms of Mutagenesis"},{"key":"10.1016\/j.bioorg.2025.108950_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2017.08.045","article-title":"A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies","volume":"140","author":"Borisa","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2025.108950_bb0580","doi-asserted-by":"crossref","first-page":"E1513","DOI":"10.1073\/pnas.1110287109","article-title":"Aurora B kinase phosphorylates and instigates degradation of p53","volume":"109","author":"Gully","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108950_bb0585","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc1502","article-title":"Aurora-kinase inhibitors as anticancer agents","volume":"4","author":"Keen","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1541-7786.MCR-06-0208","article-title":"Roles of Aurora kinases in mitosis and tumorigenesis","volume":"5","author":"Fu","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108950_bb0595","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fcell.2015.00050","article-title":"Functions of Aurora kinase C in meiosis and cancer","volume":"3","author":"Quartuccio","year":"2015","journal-title":"Frontiers Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108950_bb0600","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/2040620715607415","article-title":"Recent advances in the development of Aurora kinases inhibitors in hematological malignancies","volume":"6","author":"Choudary","year":"2015","journal-title":"Therapeutic advances in hematology"},{"key":"10.1016\/j.bioorg.2025.108950_bb0605","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1053\/j.seminoncol.2015.09.022","article-title":"Aurora kinase inhibitors in oncology clinical trials: current state of the progress","author":"Falchook","year":"2015","journal-title":"Seminars in oncology, Elsevier"},{"key":"10.1016\/j.bioorg.2025.108950_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113673","article-title":"Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization","volume":"224","author":"Li","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108950_bb0615","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/jcc.10306","article-title":"Detailed analysis of grid-based molecular docking: a case study of CDOCKER\u2014A CHARMm-based MD docking algorithm","volume":"24","author":"Wu","year":"2003","journal-title":"J. Comput. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108950_bb0620","first-page":"2031","article-title":"Targeting the BDNF\/TrkB pathway for the treatment of tumors","volume":"17","author":"Meng","year":"2019","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0625","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3835(02)00723-1","article-title":"Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma","volume":"193","author":"Jaboin","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108950_bb0630","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s40265-016-0661-5","article-title":"Cabozantinib: a review in advanced renal cell carcinoma","volume":"76","author":"Al-Salama","year":"2016","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0635","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a Pan\u2013TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"15_Supplement","key":"10.1016\/j.bioorg.2025.108950_bb0640","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1158\/1538-7445.AM2015-4529","article-title":"Pharmacokinetics (PK) of LOXO-101 during the first-in-human phase I study in patients with advanced solid tumors: interim update","volume":"75","author":"Burris","year":"2015","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108950_bb0645","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0650","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1038\/ncomms7623","article-title":"Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice","volume":"6","author":"Garofalo","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0655","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.05.029","article-title":"Environmental and genetic activation of a brain-adipocyte BDNF\/leptin axis causes cancer remission and inhibition","volume":"142","author":"Cao","year":"2010","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108950_bb0660","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1158\/2326-6066.CIR-15-0297","article-title":"Environmental and genetic activation of hypothalamic BDNF modulates T-cell immunity to exert an anticancer phenotype","volume":"4","author":"Xiao","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bioorg.2025.108950_bb0665","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pbb.2013.06.005","article-title":"Effects of AS2586114, a soluble epoxide hydrolase inhibitor, on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine","volume":"110","author":"Ma","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bioorg.2025.108950_bb0670","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fphar.2019.00420","article-title":"Soluble epoxide hydrolase inhibitor: a novel potential therapeutic or prophylactic drug for psychiatric disorders","volume":"10","author":"Ren","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108950_bb0675","doi-asserted-by":"crossref","unstructured":"H. Yu, Z.-y. Chen, The role of BDNF in depression on the basis of its location in the neural circuitry, Acta Pharmacol. Sin. 32(1) (2011) 3\u201311.","DOI":"10.1038\/aps.2010.184"},{"key":"10.1016\/j.bioorg.2025.108950_bb0680","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/NDT.S5700","article-title":"Brain-derived neurotrophic factor: role in depression and suicide","author":"Dwivedi","year":"2009","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bioorg.2025.108950_bb0685","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","article-title":"BDNF\u2013a key transducer of antidepressant effects","volume":"102","author":"Bj\u00f6rkholm","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0690","first-page":"22","article-title":"SSRI antidepressant medications: adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Primary Care Companion J. Clinical Psychiatry"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108950_bb0695","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108950_bb0700","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/ph14080704","article-title":"Do small molecules activate the TrkB receptor in the same manner as BDNF? Limitations of published TrkB low molecular agonists and screening for novel TrkB orthosteric agonists","volume":"14","author":"Pankiewicz","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108950_bb0705","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108950_bb0710","first-page":"91","article-title":"Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer","author":"Tran","year":"2016","journal-title":"Lung Cancer: Targets Therapy"},{"key":"10.1016\/j.bioorg.2025.108950_bb0715","series-title":"Mobocertinib in Non-small Cell Lung cancer, Drugs of Today (Barcelona, Spain: 1998)","first-page":"523","volume":"vol. 58(11)","author":"Liu","year":"2022"},{"issue":"21","key":"10.1016\/j.bioorg.2025.108950_bb0720","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1016\/j.bmcl.2017.09.048","article-title":"Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors","volume":"27","author":"Romu","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108950_bb0725","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-017-0776-3","article-title":"Brigatinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.bioorg.2025.108950_bb0730","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s40265-023-01959-5","article-title":"Sunvozertinib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108950_bb0735","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108950_bb0740","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation","volume":"15","author":"Shi","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108950_bb0745","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3390\/cancers15071943","article-title":"TrkA co-receptors: the janus face of TrkA?","volume":"15","author":"Trouvilliez","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.108950_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137790","article-title":"Anticancer activity of new triazolopyrimidine linked coumarin and quinolone hybrids: synthesis, molecular modeling, TrkA, PI3K\/AKT and EGFR inhibition","volume":"1305","author":"Batran","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108950_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107962","article-title":"Unveiling the potential anticancer activity of new dihydropyrimidines through dual inhibition of EGFR and TrkA: design, synthesis, and in silico study","volume":"154","author":"Slly","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108950_bb0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-283","article-title":"Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor \u03b1 signalling and results in tamoxifen insensitive proliferation","volume":"14","author":"Moerkens","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0765","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-022-02389-z","article-title":"Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer","volume":"41","author":"Yang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"36","key":"10.1016\/j.bioorg.2025.108950_bb0770","doi-asserted-by":"crossref","first-page":"39028","DOI":"10.18632\/oncotarget.5494","article-title":"NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.bioorg.2025.108950_bb0775","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/onc.2009.61","article-title":"TrkA overexpression enhances growth and metastasis of breast cancer cells","volume":"28","author":"Lagadec","year":"2009","journal-title":"Oncogene"},{"issue":"48","key":"10.1016\/j.bioorg.2025.108950_bb0780","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108950_bb0785","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1021\/acsmedchemlett.5b00050","article-title":"(R)-2-Phenylpyrrolidine substituted imidazopyridazines: a new class of potent and selective pan-TRK inhibitors","volume":"6","author":"Choi","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108950_bb0790","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1073\/pnas.1611577114","article-title":"Structural characterization of nonactive site, TrkA-selective kinase inhibitors","volume":"114","author":"Su","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108950_bb0795","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1634\/theoncologist.2010-0408","article-title":"Current status of SRC inhibitors in solid tumor malignancies","volume":"16","author":"Puls","year":"2011","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0800","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: the network approach might help drug design","volume":"26","author":"Csermely","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108950_bb0805","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/fon.10.26","article-title":"Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer","volume":"6","author":"Altieri","year":"2010","journal-title":"Future Oncol."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108950_bb0810","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1016\/j.bmc.2018.10.004","article-title":"Novel 5, 6-disubstituted pyrrolo [2, 3-d] pyrimidine derivatives as broad spectrum antiproliferative agents: synthesis, cell based assays, kinase profile and molecular docking study","volume":"26","author":"Lee","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108950_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115918","article-title":"Design and synthesis of certain 7-Aryl-2-Methyl-3-Substituted Pyrazolo {1, 5-a} Pyrimidines as multikinase inhibitors","volume":"262","author":"Al-Qadhi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108950_bb0820","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ROS oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108950_bb0825","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.molonc.2014.06.001","article-title":"The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition","volume":"8","author":"Ardini","year":"2014","journal-title":"Mol. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108950_bb0830","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cam4.413","article-title":"Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK","volume":"4","author":"Fontana","year":"2015","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0835","doi-asserted-by":"crossref","first-page":"djv306","DOI":"10.1093\/jnci\/djv306","article-title":"Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer","volume":"108","author":"Sartore-Bianchi","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108950_bb0840","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/bjc.2015.401","article-title":"Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer","volume":"113","author":"Amatu","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.108950_bb0845","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent-front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108950_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112744","article-title":"Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl) vinyl)-1H-indazol-6-yl) thiazol-2-yl)-2-(4-methylpiperazin-1-yl) acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants","volume":"207","author":"Wang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108950_bb0855","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1021\/acs.jmedchem.8b00938","article-title":"Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy) quinazolin-4-yl] amino} phenyl)-2-[4-(propan-2-yl)-1 H-1, 2, 3-triazol-1-yl] acetamide (AZD3229), a potent Pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors","volume":"61","author":"Kettle","year":"2018","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108950_bb0860","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108950_bb0865","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3923\/ijp.2015.806.813","article-title":"Antimelanomal activities of some newly synthesized pyrrolotriazolopyrimidines and pyrrolotetrazolopyrimidines and their derivatives","volume":"11","author":"Ibrahim","year":"2015","journal-title":"Int. J. Pharmacol."},{"issue":"30","key":"10.1016\/j.bioorg.2025.108950_bb0870","doi-asserted-by":"crossref","first-page":"8841","DOI":"10.1002\/ange.201501104","article-title":"Fragment-based discovery of a dual pan-RET\/VEGFR2 kinase inhibitor optimized for single-agent polypharmacology","volume":"127","author":"Frett","year":"2015","journal-title":"Angew. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2025.108950_bb0875","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1111\/bph.14395","article-title":"Drug resistance profiles of mutations in the RET kinase domain","volume":"175","author":"Liu","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0880","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2025.108950_bb0885","doi-asserted-by":"crossref","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","article-title":"TRK inhibitors in TRK fusion-positive cancers","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108950_bb0890","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1677\/ERC-08-0213","article-title":"Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474","volume":"16","author":"Carlomagno","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bioorg.2025.108950_bb0895","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2019.04.053","article-title":"Targeting tropomyosin receptor kinase for cancer therapy","volume":"175","author":"Miao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108950_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112552","article-title":"Design, synthesis, and Structure\u2013Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors","volume":"203","author":"Duan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"28","key":"10.1016\/j.bioorg.2025.108950_bb0905","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.2174\/0929867327666200102120652","article-title":"Recent advances in the rational drug design based on multi-target ligands","volume":"27","author":"Yang","year":"2020","journal-title":"Curr. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:23:25Z","timestamp":1760559805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":181,"alternative-id":["S0045206825008302"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108950","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review: recent developments of co-targeted TRK (tropomyosin receptor kinases) inhibitors for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108950"}}